Evofem Biosciences (EVFM) Competitors $0.0093 0.00 (-3.13%) As of 11:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. MTNB, TCRT, QLGN, DRMA, REVB, CMND, SNGX, ALBT, VRAX, and CNSPShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Matinas Biopharma (MTNB), Alaunos Therapeutics (TCRT), Qualigen Therapeutics (QLGN), Dermata Therapeutics (DRMA), Revelation Biosciences (REVB), Clearmind Medicine (CMND), Soligenix (SNGX), Avalon GloboCare (ALBT), Virax Biolabs Group (VRAX), and CNS Pharmaceuticals (CNSP). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Matinas Biopharma Alaunos Therapeutics Qualigen Therapeutics Dermata Therapeutics Revelation Biosciences Clearmind Medicine Soligenix Avalon GloboCare Virax Biolabs Group CNS Pharmaceuticals Evofem Biosciences (NASDAQ:EVFM) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Do insiders and institutionals have more ownership in EVFM or MTNB? 0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are held by institutional investors. 0.2% of Evofem Biosciences shares are held by insiders. Comparatively, 4.6% of Matinas Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor EVFM or MTNB? In the previous week, Evofem Biosciences had 2 more articles in the media than Matinas Biopharma. MarketBeat recorded 2 mentions for Evofem Biosciences and 0 mentions for Matinas Biopharma. Matinas Biopharma's average media sentiment score of 0.00 beat Evofem Biosciences' score of -0.50 indicating that Matinas Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Evofem Biosciences Negative Matinas Biopharma Neutral Which has more risk and volatility, EVFM or MTNB? Evofem Biosciences has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500. Is EVFM or MTNB more profitable? Matinas Biopharma has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Evofem Biosciences-46.42% -91.97% -61.93% Matinas Biopharma N/A -123.06%-94.28% Which has higher valuation and earnings, EVFM or MTNB? Evofem Biosciences has higher revenue and earnings than Matinas Biopharma. Matinas Biopharma is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvofem Biosciences$11.39M0.10$52.98M-$0.05-0.19Matinas BiopharmaN/AN/A-$22.94M-$3.86-0.23 Do analysts rate EVFM or MTNB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEvofem Biosciences beats Matinas Biopharma on 7 of the 13 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.10M$784.23M$5.50B$9.55BDividend YieldN/A4.84%4.71%4.14%P/E Ratio-0.011.3028.7823.91Price / Sales0.1027.01438.3895.11Price / CashN/A19.5635.6858.35Price / Book0.006.598.225.62Net Income$52.98M-$4.20M$3.25B$265.35M7 Day PerformanceN/A-4.48%-0.73%-0.89%1 Month PerformanceN/A-0.96%5.52%4.98%1 Year PerformanceN/A18.29%28.79%23.50% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences0.9159 of 5 stars$0.01-3.1%N/A-4.0%$1.10M$11.39M-0.01120News CoverageShort Interest ↑MTNBMatinas Biopharma0.6034 of 5 stars$0.930.0%N/AN/A$4.73MN/A-0.1930TCRTAlaunos Therapeutics0.5101 of 5 stars$3.00+6.8%N/A+15.3%$4.60M$10K-1.1840Upcoming EarningsGap UpQLGNQualigen TherapeuticsN/A$2.80flatN/A-81.3%$4.58MN/A0.0050DRMADermata Therapeutics1.7494 of 5 stars$0.70+0.5%$3.00+326.8%-74.3%$4.46MN/A-0.048Positive NewsShort Interest ↑Gap UpREVBRevelation Biosciences0.3991 of 5 stars$2.69-6.6%N/A-95.1%$4.42MN/A-0.0110Positive NewsUpcoming EarningsCMNDClearmind Medicine0.2871 of 5 stars$1.02-1.0%N/A-22.2%$4.39MN/A-0.93N/ANews CoverageShort Interest ↑SNGXSoligenix2.1111 of 5 stars$1.28-3.0%$6.00+368.8%-15.1%$4.31M$120K-0.3020News CoverageUpcoming EarningsShort Interest ↑ALBTAvalon GloboCare1.1743 of 5 stars$2.97+30.8%N/A-45.5%$4.30M$1.33M-0.155Positive NewsShort Interest ↑Gap UpHigh Trading VolumeVRAXVirax Biolabs Group3.1528 of 5 stars$0.95-3.6%$3.00+214.8%-26.0%$4.29M$10K0.005CNSPCNS Pharmaceuticals2.0859 of 5 stars$8.19-7.1%$300.00+3,563.0%-93.4%$4.01MN/A0.005Upcoming Earnings Related Companies and Tools Related Companies Matinas Biopharma Alternatives Alaunos Therapeutics Alternatives Qualigen Therapeutics Alternatives Dermata Therapeutics Alternatives Revelation Biosciences Alternatives Clearmind Medicine Alternatives Soligenix Alternatives Avalon GloboCare Alternatives Virax Biolabs Group Alternatives CNS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredDebt Crisis Warning: How to Protect Your Wealth Before August 31stOn August 31st, the U.S. runs out of “extraordinary measures” to avoid default—and Washington insiders are alr...American Alternative | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredGuess Who the Gvt Could Partner With Next?The Government Just Made a $400M Bet. Who's Next? A $100 trillion wealth shift is quietly underway... and t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
